Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed/refractory leukemia or myelodysplasia

Outcomes of patients with persistent high-risk leukemia or myelodysplasia prior to allogeneic hematopoietic cell transplantation are dismal. We therefore conducted a phase I trial evaluating the use of CD45-targeted radiotherapy preceding hematopoietic cell transplantation with the goal of improving...

Descripción completa

Detalles Bibliográficos
Autores principales: Vo, Phuong, Gooley, Ted A., Rajendran, Joseph G., Fisher, Darrell R., Orozco, Johnnie J., Green, Damian J., Gopal, Ajay K., Haaf, Robyn, Nartea, Margaret, Storb, Rainer, Appelbaum, Frederick R., Press, Oliver W., Pagel, John M., Sandmaier, Brenda M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271581/
https://www.ncbi.nlm.nih.gov/pubmed/31582553
http://dx.doi.org/10.3324/haematol.2019.229492

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271581/
https://www.ncbi.nlm.nih.gov/pubmed/31582553
http://dx.doi.org/10.3324/haematol.2019.229492

Ejemplares similares